Login
Sign up

[ARS] Minerva Neurosciences, Inc. SEC Filing

Filing Impact

(No impact)

Filing Sentiment

(Neutral)

Form Type

ARS

11/24/2025 - 04:07 PM

ARS - Minerva Neurosciences, Inc.

ARS Filing - Minerva Neurosciences, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Minerva Neurosciences, Inc. (NERV)

Acceptance Date: 2025-11-24T16:07:53.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Minerva Neurosci

NASDAQ:NERV

NERV Rankings

#5828 Ranked by Market Cap

N/A Ranked by Dividends

NERV Latest News

Nov 19, 2025

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

Nov 5, 2025

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Oct 21, 2025

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

Aug 14, 2025

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

May 13, 2025

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

NERV Latest SEC Filings

Nov 24, 2025

[DEF 14A] Minerva Neurosciences, Inc. Definitive Proxy Statement

Nov 19, 2025

[8-K] Minerva Neurosciences, Inc. Reports Material Event

Nov 18, 2025

[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity

Nov 18, 2025

[Form 3] Minerva Neurosciences, Inc. Initial Statement of Beneficial Ownership

Nov 5, 2025

[10-Q] Minerva Neurosciences, Inc. Quarterly Earnings Report

NERV Stock Data

Market Cap 27.55M

Float 5.44M

Insiders Ownership 22.26%

Institutions Ownership 27.99%

Short Percent 0.66%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City BURLINGTON